{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:42:07Z","timestamp":1794465727023,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["31252"],"award-info":[{"award-number":["31252"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG2019_23520"],"award-info":[{"award-number":["IG2019_23520"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR M4C2I1.3 Heal Italia project PE00000019"],"award-info":[{"award-number":["PNRR M4C2I1.3 Heal Italia project PE00000019"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment of ovarian cancer has significantly improved since the introduction of PARP inhibitors (PARPi), small molecules designed to directly target and kill cancer cells with deficiencies in homologous recombination (HR) pathway. However, nearly half of patients present with HR-proficient tumors, rendering them not eligible for PARPi-based therapies and underscoring the urgent need for alternative treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Oxidative metabolism has been altered either by silencing the mitochondria regulator PGC-1\u03b2 or by using the OXPHOS inhibitor IACS-010759. The metabolic alterations were characterized by seahorse analysis and metabolomic profiling. DNA damage and repair were evaluated by immunofluorescence and confocal analysis. Efficacy and tolerability of the combination of PARP and OXPHOS inhibitors were investigated in preclinical trials employing patient-derived ovarian cancer xenografts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our findings reveal that PGC-1\u03b2 silencing sensitizes ovarian cancer cells to PARPi by impairing oxidative metabolism, reducing succinate levels and decreasing Fen1 succinylation and SUMOylation. The impairment of these post-translational modifications hinders Fen1 activation and prevents the recruitment of Rad51, resulting in a HR-deficient-like phenotype. The translational relevance of the findings has been validated using the OXPHOS inhibitor IACS-010759, which synergizes with PARPi to inhibit cancer cell proliferation, while sparing normal cells. Furthermore, the combination therapy delays tumor progression in ovarian cancer xenografts not responsive to PARPi, independently from their HR status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeting mitochondrial metabolism depicts a novel mechanism to modulate DNA repair and enhance PARPi sensitivity. This approach broadens the therapeutic applicability of PARP inhibitors beyond HR-deficient tumors and offers promising avenues to overcome resistance in ovarian cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03641-6","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:24:18Z","timestamp":1768346658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Laura","family":"Formenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Abramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Dellavedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dematteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Decio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Grasselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fabbrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Giavazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"3641_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399. https:\/\/doi.org\/10.2147\/IJWH.S197604.","journal-title":"Int J Womens Health"},{"key":"3641_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ejca.2021.08.023","volume":"157","author":"I Vergote","year":"2021","unstructured":"Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, et al. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1\/ENGOT-ov25 trials evaluating maintenance Olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021;157:415\u201323. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.023.","journal-title":"Eur J Cancer"},{"key":"3641_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Maintenance Olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:1721\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3.","journal-title":"Lancet Oncol"},{"key":"3641_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137. https:\/\/doi.org\/10.1038\/nature03443.","journal-title":"Nature"},{"key":"3641_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5:387\u201393. https:\/\/doi.org\/10.1016\/j.molonc.2011.07.001.","journal-title":"Mol Oncol"},{"key":"3641_CR6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonz\u00e1lez-Mart\u00edn A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31:1148\u201359. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.004.","journal-title":"Ann Oncol"},{"key":"3641_CR7","doi-asserted-by":"publisher","first-page":"108413","DOI":"10.1016\/j.pharmthera.2023.108413","volume":"245","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang Y, Zhao G, Orsulic S, Matei D. Metabolic dependencies and targets in ovarian cancer. Pharmacol Ther. 2023;245:108413. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108413.","journal-title":"Pharmacol Ther"},{"key":"3641_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ygyno.2018.06.013","volume":"150","author":"N Li","year":"2018","unstructured":"Li N, Zhan X, Zhan X. The LncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes. Gynecol Oncol. 2018;150:343\u201354. https:\/\/doi.org\/10.1016\/j.ygyno.2018.06.013.","journal-title":"Gynecol Oncol"},{"key":"3641_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cmet.2018.09.002","volume":"29","author":"G Gentric","year":"2019","unstructured":"Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, et al. PML-Regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers. Cell Metab. 2019;29:156\u2013e17310. https:\/\/doi.org\/10.1016\/j.cmet.2018.09.002.","journal-title":"Cell Metab"},{"key":"3641_CR10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/sj.bjc.6603377","volume":"95","author":"Y Wang","year":"2006","unstructured":"Wang Y, Liu VWS, Xue WC, Cheung ANY, Ngan HYS. Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer. 2006;95:1087\u201391. https:\/\/doi.org\/10.1038\/sj.bjc.6603377.","journal-title":"Br J Cancer"},{"key":"3641_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3390\/cancers11091350","volume":"11","author":"A Signorile","year":"2019","unstructured":"Signorile A, De Rasmo D, Cormio A, Musicco C, Rossi R, Fortarezza F, et al. Human ovarian cancer tissue exhibits increase of mitochondrial biogenesis and Cristae remodeling. Cancers (Basel). 2019;11:1350. https:\/\/doi.org\/10.3390\/cancers11091350.","journal-title":"Cancers (Basel)"},{"key":"3641_CR12","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1158\/1541-7786.MCR-19-1145","volume":"18","author":"LX Zampieri","year":"2020","unstructured":"Zampieri LX, Grasso D, Bouzin C, Brusa D, Rossignol R, Sonveaux P. Mitochondria participate in chemoresistance to cisplatin in human ovarian cancer cells. Mol Cancer Res. 2020;18:1379\u201391. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-1145.","journal-title":"Mol Cancer Res"},{"key":"3641_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12967-022-03447-y","volume":"20","author":"S Sriramkumar","year":"2022","unstructured":"Sriramkumar S, Sood R, Huntington TD, Ghobashi AH, Vuong TT, Metcalfe TX, et al. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer. J Transl Med. 2022;20:246. https:\/\/doi.org\/10.1186\/s12967-022-03447-y.","journal-title":"J Transl Med"},{"key":"3641_CR14","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/0008-5472.CAN-21-1223","volume":"82","author":"C Ghilardi","year":"2022","unstructured":"Ghilardi C, Moreira-Barbosa C, Brunelli L, Ostano P, Panini N, Lupi M, et al. PGC1\u03b1\/\u03b2 expression predicts therapeutic response to oxidative phosphorylation Inhibition in ovarian cancer. Cancer Res. 2022;82:1423\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1223.","journal-title":"Cancer Res"},{"key":"3641_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cmet.2011.03.004","volume":"13","author":"P Bai","year":"2011","unstructured":"Bai P, Canto C, Oudart H, Bruny\u00e1nszki A, Cen Y, Thomas C, et al. PARP-1 Inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011;13:461\u20138. https:\/\/doi.org\/10.1016\/j.cmet.2011.03.004.","journal-title":"Cell Metab"},{"key":"3641_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjamd.2016.22","volume":"2","author":"LE Brace","year":"2016","unstructured":"Brace LE, Vose SC, Stanya K, Gathungu RM, Marur VR, Longchamp A, et al. Increased oxidative phosphorylation in response to acute and chronic DNA damage. Npj aging mech dis. Nat Publishing Group. 2016;2:1\u201311. https:\/\/doi.org\/10.1038\/npjamd.2016.22.","journal-title":"Nat Publishing Group"},{"key":"3641_CR17","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1091\/mbc.E18-10-0650","volume":"30","author":"MM Murata","year":"2019","unstructured":"Murata MM, Kong X, Moncada E, Chen Y, Imamura H, Wang P, et al. NAD\u2009+\u2009consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival. MBoC Am Soc Cell Biology (mboc). 2019;30:2584\u201397. https:\/\/doi.org\/10.1091\/mbc.E18-10-0650.","journal-title":"MBoC Am Soc Cell Biology (mboc)"},{"key":"3641_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/cells8091047","volume":"8","author":"Y Ke","year":"2019","unstructured":"Ke Y, Wang C, Zhang J, Zhong X, Wang R, Zeng X, et al. The role of PARPs in Inflammation-and Metabolic-Related diseases: molecular mechanisms and beyond. Cells. 2019;8:1047. https:\/\/doi.org\/10.3390\/cells8091047.","journal-title":"Cells"},{"key":"3641_CR19","doi-asserted-by":"publisher","unstructured":"Lahiguera \u00c1, Hyro\u0161\u0161ov\u00e1 P, Figueras A, Garz\u00f3n D, Moreno R, Soto-Cerrato V, et al. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. EMBO Mol Med. 2020;12. https:\/\/doi.org\/10.15252\/emmm.201911217.","DOI":"10.15252\/emmm.201911217"},{"issue":"12","key":"3641_CR20","doi-asserted-by":"publisher","first-page":"2200060","DOI":"10.1002\/adbi.202200060","volume":"6","author":"JJ Lee","year":"2022","unstructured":"Lee JJ, Kang HJ, Kim SS, Charton C, Kim J, Lee J. Unraveling the transcriptomic signatures of homologous recombination deficiency in ovarian cancers. Adv Biology. 2022;6:e2200060 https:\/\/doi.org\/10.1002\/adbi.202200060.","journal-title":"Adv Biology"},{"key":"3641_CR21","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","volume":"76","author":"J Walton","year":"2016","unstructured":"Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, et al. CRISPR\/Cas9-Mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian High-Grade serous carcinoma. Cancer Res. 2016;76:6118\u201329. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1272.","journal-title":"Cancer Res"},{"key":"3641_CR22","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1158\/1078-0432.CCR-05-1615","volume":"12","author":"E Naumova","year":"2006","unstructured":"Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, et al. The vascular targeting property of Paclitaxel is enhanced by SU6668, a receptor tyrosine kinase Inhibitor, causing apoptosis of endothelial cells and Inhibition of angiogenesis. Clin Cancer Res. 2006;12:1839\u201349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1615.","journal-title":"Clin Cancer Res"},{"key":"3641_CR23","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3390\/cells9081766","volume":"9","author":"E Caiola","year":"2020","unstructured":"Caiola E, Colombo M, Sestito G, Lupi M, Marabese M, Pastorelli R, et al. Glutaminase Inhibition on NSCLC depends on extracellular Alanine exploitation. Cells. 2020;9:1766. https:\/\/doi.org\/10.3390\/cells9081766.","journal-title":"Cells"},{"key":"3641_CR24","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555\u201377. https:\/\/doi.org\/10.1038\/sj.bjc.6605642.","journal-title":"Br J Cancer"},{"key":"3641_CR25","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1158\/0008-5472.CAN-14-0274","volume":"74","author":"F Ricci","year":"2014","unstructured":"Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, et al. Patient-Derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 2014;74:6980\u201390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0274.","journal-title":"Cancer Res"},{"key":"3641_CR26","doi-asserted-by":"publisher","first-page":"C657","DOI":"10.1152\/ajpcell.00137.2020","volume":"319","author":"R Shi","year":"2020","unstructured":"Shi R, Wang Y, Gao Y, Xu X, Mao S, Xiao Y, et al. Succinylation at a key residue of FEN1 is involved in the DNA damage response to maintain genome stability. Am J Physiol Cell Physiol. 2020;319:C657\u201366. https:\/\/doi.org\/10.1152\/ajpcell.00137.2020.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3641_CR27","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753.","journal-title":"Cancer Res"},{"key":"3641_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","volume":"13","author":"J Murai","year":"2014","unstructured":"Murai J, Huang S-YN, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with Olaparib and Rucaparib. Mol Cancer Ther. 2014;13:433\u201343. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0803.","journal-title":"Mol Cancer Ther"},{"key":"3641_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13045-021-01196-x","volume":"14","author":"F Bizzaro","year":"2021","unstructured":"Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, et al. VEGF pathway Inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. J Hematol Oncol. 2021;14:186. https:\/\/doi.org\/10.1186\/s13045-021-01196-x.","journal-title":"J Hematol Oncol"},{"key":"3641_CR30","first-page":"2912","volume":"7","author":"MI Nicoletti","year":"2001","unstructured":"Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer drug screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res. 2001;7:2912\u201322.","journal-title":"Clin Cancer Res"},{"key":"3641_CR31","doi-asserted-by":"publisher","unstructured":"Punekar S, Cho DC. Novel therapeutics affecting metabolic Pathways. Am Soc clin oncol Educ book. Wolters Kluwer; 2019. pp. e79\u201387. https:\/\/doi.org\/10.1200\/EDBK_238499.","DOI":"10.1200\/EDBK_238499"},{"key":"3641_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-020-00320-2","volume":"21","author":"G Bergers","year":"2021","unstructured":"Bergers G, Fendt S-M. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21:162\u201380. https:\/\/doi.org\/10.1038\/s41568-020-00320-2.","journal-title":"Nat Rev Cancer"},{"key":"3641_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28. https:\/\/doi.org\/10.1186\/s12943-021-01316-8.","journal-title":"Mol Cancer"},{"key":"3641_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fonc.2020.00281","volume":"10","author":"MA Desbats","year":"2020","unstructured":"Desbats MA, Giacomini I, Prayer-Galetti T, Montopoli M. Metabolic plasticity in chemotherapy resistance. Front Oncol. 2020;10:281. https:\/\/doi.org\/10.3389\/fonc.2020.00281.","journal-title":"Front Oncol"},{"key":"3641_CR35","doi-asserted-by":"publisher","first-page":"633305","DOI":"10.3389\/fcell.2021.633305","volume":"9","author":"T Sobanski","year":"2021","unstructured":"Sobanski T, Rose M, Suraweera A, O\u2019Byrne K, Richard DJ, Bolderson E. Cell metabolism and DNA repair pathways: implications for cancer therapy. Front Cell Dev Biol. 2021;9:633305. https:\/\/doi.org\/10.3389\/fcell.2021.633305.","journal-title":"Front Cell Dev Biol"},{"key":"3641_CR36","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/febs.13175","volume":"282","author":"JA Villena","year":"2015","unstructured":"Villena JA. New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. FEBS J. 2015;282:647\u201372. https:\/\/doi.org\/10.1111\/febs.13175.","journal-title":"FEBS J"},{"key":"3641_CR37","doi-asserted-by":"publisher","first-page":"1404441","DOI":"10.3389\/fimmu.2024.1404441","volume":"15","author":"H Huang","year":"2024","unstructured":"Huang H, Li G, He Y, Chen J, Yan J, Zhang Q, et al. Cellular succinate metabolism and signaling in inflammation: implications for therapeutic intervention. Front Immunol. 2024;15:1404441. https:\/\/doi.org\/10.3389\/fimmu.2024.1404441.","journal-title":"Front Immunol"},{"key":"3641_CR38","doi-asserted-by":"publisher","first-page":"115713","DOI":"10.1016\/j.biopha.2023.115713","volume":"168","author":"Z Liu","year":"2023","unstructured":"Liu Z, Wang R, Wang Y, Duan Y, Zhan H. Targeting succinylation-mediated metabolic reprogramming as a potential approach for cancer therapy. Biomed Pharmacother. 2023;168:115713. https:\/\/doi.org\/10.1016\/j.biopha.2023.115713.","journal-title":"Biomed Pharmacother"},{"key":"3641_CR39","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1128\/MCB.25.16.6948-6955.2005","volume":"25","author":"K Kikuchi","year":"2005","unstructured":"Kikuchi K, Taniguchi Y, Hatanaka A, Sonoda E, Hochegger H, Adachi N, et al. Fen-1 facilitates homologous recombination by removing divergent sequences at DNA break ends. Mol Cell Biol. 2005;25:6948\u201355. https:\/\/doi.org\/10.1128\/MCB.25.16.6948-6955.2005.","journal-title":"Mol Cell Biol"},{"key":"3641_CR40","doi-asserted-by":"publisher","first-page":"10557","DOI":"10.3390\/ijms221910557","volume":"22","author":"P Gralewska","year":"2021","unstructured":"Gralewska P, Gajek A, Marczak A, Rogalska A. Metformin affects Olaparib sensitivity through induction of apoptosis in epithelial ovarian cancer cell lines. Int J Mol Sci Multidisciplinary Digit Publishing Inst. 2021;22:10557. https:\/\/doi.org\/10.3390\/ijms221910557.","journal-title":"Int J Mol Sci Multidisciplinary Digit Publishing Inst"},{"key":"3641_CR41","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/cam4.2738","volume":"9","author":"Q Wang","year":"2020","unstructured":"Wang Q, L\u00f3pez-Ozuna VM, Baloch T, Bithras J, Amin O, Kessous R, et al. Biguanides in combination with Olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through Inhibition of snail. Cancer Med. 2020;9:1307\u201320. https:\/\/doi.org\/10.1002\/cam4.2738.","journal-title":"Cancer Med"},{"key":"3641_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ygyno.2016.06.005","volume":"142","author":"M Hijaz","year":"2016","unstructured":"Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, et al. Preclinical evaluation of Olaparib and Metformin combination in BRCA1 wildtype ovarian cancer. Gynecol Oncol. 2016;142:323\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2016.06.005.","journal-title":"Gynecol Oncol"},{"key":"3641_CR43","doi-asserted-by":"publisher","first-page":"608","DOI":"10.20517\/cdr.2019.50","volume":"2","author":"A Mweempwa","year":"2019","unstructured":"Mweempwa A, Wilson MK. Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. Cancer Drug Resist. 2019;2:608\u201317. https:\/\/doi.org\/10.20517\/cdr.2019.50.","journal-title":"Cancer Drug Resist"},{"key":"3641_CR44","unstructured":"Gustave Roussy C, Campus G, Paris. Jan. An Open-label, Multicentric, Phase Ib\/II Study to Assess the Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib Since at Least 6 Months. clinicaltrials.gov; 2023. Report No.: NCT04826198. https:\/\/clinicaltrials.gov\/study\/NCT04826198."},{"key":"3641_CR45","unstructured":"MD Anderson Cancer Center. EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition. clinicaltrials.gov; 2023 Oct. Report No.: NCT03579316. https:\/\/clinicaltrials.gov\/study\/NCT03579316."},{"key":"3641_CR46","unstructured":"University Health Network, Toronto. Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance. clinicaltrials.gov; 2023 Jul. Report No.: NCT05065021. https:\/\/clinicaltrials.gov\/study\/NCT05065021."},{"key":"3641_CR47","doi-asserted-by":"publisher","unstructured":"Veneziani AC, Scott C, Wakefield MJ, Tinker AV, Lheureux S, Ltd STM. 2023;15:17588359231157644. https:\/\/doi.org\/10.1177\/17588359231157644.","DOI":"10.1177\/17588359231157644"},{"key":"3641_CR48","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036\u201346. https:\/\/doi.org\/10.1038\/s41591-018-0052-4.","journal-title":"Nat Med"},{"key":"3641_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115\u201326. https:\/\/doi.org\/10.1038\/s41591-022-02103-8.","journal-title":"Nat Med"},{"key":"3641_CR50","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(18)30786-1.","journal-title":"Lancet Oncol"},{"key":"3641_CR51","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/biom12071007","volume":"12","author":"F Yang","year":"2022","unstructured":"Yang F, Hu Z, Guo Z. Small-Molecule inhibitors targeting FEN1 for cancer therapy. Biomolecules. 2022;12:1007. https:\/\/doi.org\/10.3390\/biom12071007.","journal-title":"Biomolecules"},{"key":"3641_CR52","doi-asserted-by":"publisher","first-page":"eadl6445","DOI":"10.1126\/scisignal.adl6445","volume":"17","author":"K Watanabe","year":"2024","unstructured":"Watanabe K, Yamamoto T, Fujita T, Hino S, Hino Y, Yamazaki K, et al. Metabolically inducing defects in DNA repair sensitizes BRCA-wild-type cancer cells to replication stress. Sci Signal. 2024;17:eadl6445. https:\/\/doi.org\/10.1126\/scisignal.adl6445.","journal-title":"Sci Signal"},{"key":"3641_CR53","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-019-08530-5","volume":"10","author":"C Bian","year":"2019","unstructured":"Bian C, Zhang C, Luo T, Vyas A, Chen S-H, Liu C, et al. NADP\u2009+\u2009is an endogenous PARP inhibitor in DNA damage response and tumor suppression. Nat Commun. 2019;10:693. https:\/\/doi.org\/10.1038\/s41467-019-08530-5.","journal-title":"Nat Commun"},{"key":"3641_CR54","doi-asserted-by":"publisher","first-page":"102337","DOI":"10.1016\/j.tranon.2025.102337","volume":"54","author":"MI Frederick","year":"2025","unstructured":"FrederickMI, Fyle E, Clouvel A, Abdesselam D, Hassan S. Targeting FEN1\/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer. Transl Oncol. 2025;54:102337. https:\/\/doi.org\/10.1016\/j.tranon.2025.102337.","journal-title":"Transl Oncol"},{"key":"3641_CR55","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.3390\/ijms25042110","volume":"25","author":"J Berfelde","year":"2024","unstructured":"Berfelde J, Hildebrand LS, Kuhlmann L, Fietkau R, Distel LV. FEN1 Inhibition as a potential novel targeted therapy against breast cancer and the prognostic relevance of FEN1. Int J Mol Sci Multidisciplinary Digit Publishing Inst. 2024;25:2110. https:\/\/doi.org\/10.3390\/ijms25042110.","journal-title":"Int J Mol Sci Multidisciplinary Digit Publishing Inst"},{"key":"3641_CR56","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/emboj.2010.330","volume":"30","author":"C Cosentino","year":"2011","unstructured":"Cosentino C, Grieco D, Costanzo V. ATM activates the Pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J. 2011;30:546\u201355. https:\/\/doi.org\/10.1038\/emboj.2010.330.","journal-title":"EMBO J"},{"key":"3641_CR57","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.molcel.2017.06.008","volume":"67","author":"S Sivanand","year":"2017","unstructured":"Sivanand S, Rhoades S, Jiang Q, Lee JV, Benci J, Zhang J, et al. Nuclear acetyl-CoA production by ACLY promotes homologous recombination. Mol Cell. 2017;67:252\u2013e2656. https:\/\/doi.org\/10.1016\/j.molcel.2017.06.008.","journal-title":"Mol Cell"},{"key":"3641_CR58","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1038\/s41467-022-33903-8","volume":"13","author":"H-L Wang","year":"2022","unstructured":"Wang H-L, Chen Y, Wang Y-Q, Tao E-W, Tan J, Liu Q-Q, et al. Sirtuin5 protects colorectal cancer from DNA damage by keeping nucleotide availability. Nat Commun. 2022;13:6121. https:\/\/doi.org\/10.1038\/s41467-022-33903-8.","journal-title":"Nat Commun"},{"key":"3641_CR59","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/s41467-025-56781-2","volume":"16","author":"F Lang","year":"2025","unstructured":"Lang F, Kaur K, Fu H, Zaheer J, Ribeiro DL, Aladjem MI, et al. D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming. Nat Commun. 2025;16:1431. https:\/\/doi.org\/10.1038\/s41467-025-56781-2.","journal-title":"Nat Commun"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03641-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03641-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03641-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:42:37Z","timestamp":1781628157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03641-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3641"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03641-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving animals and their care were conducted in conformity with the laws, regulations, and policies governing the care and use of laboratory animals: Italian Governing Law (D.lgs 26\/2014, authorization number 19\/2008-A issued March 6th 2008, by the Ministry of Health); Mario Negri Institutional regulations and policies that provide internal authorization for people conducting animal experiments (Quality Management System Certificate, UNI EN ISO 9001:2015 \u2013 regulation no. 6121); the NIH Guide for the Care and Use of Laboratory Animals (2011 edition); EU directives and guidelines (EEC Council Directive 2010\/63\/UE), and were in line with the guidelines for the welfare and use of animals in cancer research [\n                      \n                      ]. Animal studies were approved by the Mario Negri Institute Animal Care and Use Committee (IACUC) and authorized by the Italian Ministry of Health (authorization no. 393\/2022- PR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}